INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Disposition to issuerVerified data

Lupher, Jr. Mark L. reported ADVM

Director · Adverum Biotechnologies, Inc. · Adverum Biotechnologies, Inc. — Stock Option (Right to Buy)

Side
D
Value
—
Shares
4,000
Price
—
Executed
Dec 9, 2025
Disclosed
Dec 10, 2025
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Dec 9 executedDec 10, 2025 disclosed

ADVM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Disposition to issuer — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ADVM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    10.4K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Hong SooDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    10.5K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Hong SooDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    4,000 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    21.0K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    LL
    Lupher, Jr. Mark L.Director
    ADVMAdverum Biotechnologies, Inc.
    Tender of shares
    		U—
    13.0K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    1,250 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    2,000 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    8,000 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    4,500 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    2,500 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kiss SzilardDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    2,500 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Hong SooDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    8,000 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Hong SooDirector
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    10.4K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER
    ADVMAdverum Biotechnologies, Inc.
    Tender of shares
    		U—
    54.9K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER
    ADVMAdverum Biotechnologies, Inc.
    Tender of shares
    		U—
    8,125 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    21
    SS
    Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER
    ADVMAdverum Biotechnologies, Inc.
    Grant or award
    		A—
    85.0K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER
    ADVMAdverum Biotechnologies, Inc.
    Tender of shares
    		U—
    88.3K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    40.0K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    42.5K sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    9
    SS
    Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER
    ADVMAdverum Biotechnologies, Inc.
    Disposition to issuer
    		D—
    8,500 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001775323-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 9, 2025
    Published
    Dec 10, 2025
    Ingested by INSIDER
    Nov 5, 04:28 UTC
    Last re-read
    Nov 5, 04:28 UTC

    Extracted facts

    Filer
    Lupher, Jr. Mark L.
    Role
    Director
    Transaction
    Disposition to issuerAs filed: “D”
    Asset
    Adverum Biotechnologies, Inc. — Stock Option (Right to Buy)
    Ticker
    ADVM
    Shares
    4,000
    Execution date (reported)
    Dec 9, 2025
    Owned after transaction
    0 shares
    Days from execution to publication
    1

    What this establishes

    Lupher, Jr. Mark L. filed this Form 4 reporting a disposition to issuer of ADVM on Dec 9, 2025. It became public on Dec 10, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Lupher, Jr. Mark L.cik:0001775323
    Issuer
    Adverum Biotechnologies, Inc.cik:0001501756

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for ADVM is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.